- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02670031
Response of the Myocardium to Hypertrophic Conditions in the Adult Population
Study Overview
Status
Detailed Description
According to the National Health Survey in 2010, more than 50% of adults between 60-69 years old in Singapore had hypertension. As the population ages and life expectancy continues to increase, an increasing incidence of hypertensive heart disease would be expected. Similar to aortic stenosis, left ventricular hypertrophy in patients with hypertension was associated with adverse cardiovascular outcome, independent of traditional risk factors including peripheral blood pressure. Unlike aortic stenosis (a condition with fixed obstruction), arterial hypertension is dynamic and with effective medical therapy, left ventricular hypertrophy can regress and outcome will improve. As such, contemporary guidelines recommend more aggressive blood pressure control in patients with hypertension and left ventricular hypertrophy. However, the correlation between arterial pressure and left ventricular mass is weak, particularly in treated individuals. Coupled with the inherent limitations of measuring peripheral blood pressure, it is clear that using arterial pressure to monitor progression or assess treatment response in patients with hypertensive heart disease is not optimal.
Without timely and appropriate therapies, left ventricular hypertrophy will become progressively maladaptive and ultimately the heart fails. Whilst heart failure is more commonly known by the signs and symptoms related to impaired systolic ejection fraction, heart failure with preserved ejection fraction is an increasingly recognized complex entity characterized by signs and symptoms of heart failure in the presence of preserved ejection fraction. To date, therapies that improve outcomes in heart failure with reduced ejection fraction have not shown similar benefits in patients with heart failure and preserved ejection fraction. There is no single explanation for these negative findings, but one potential reason may relate to the heterogeneity of patients recruited into these trials, and thus supporting a more targeted approach to specific phenotypes rather than a standard treatment strategy for all patients.
Therefore, a focus on the transition from compensatory left ventricular hypertrophy to ventricular decompensation is crucial not only in furthering our understanding of the pathophysiology of hypertensive heart disease, but also instrumental in designing future trials. Small studies had reported replacement myocardial fibrosis in patients with hypertension. But these studies were small and unable to establish determinants associated with myocardial fibrosis. Unlike the increasing evidence of myocardial fibrosis in aortic stenosis, the prognosis associated with myocardial fibrosis in patients with hypertension is currently not known. Although there is promising data suggesting regression in myocardial fibrosis with certain antihypertensive therapies, the effects of myocardial fibrosis regression on long-term outcome is not known. As discussed earlier, other than relying on peripheral blood pressure, there are no biomarkers to monitor response of antihypertensive therapy on regression of left ventricular mass and myocardial fibrosis.
Our investigators would establish a paradigm to demonstrate the significance of myocardial fibrosis in hypertensive heart disease; and examine other biomarkers associated with myocardial fibrosis and myocyte death that have high potential of translating into clinical application to monitor treatment response. Subsequently, the prognosis associated with myocardial fibrosis will be examined in future follow-up studies. In parallel, we will also study the effects of novel agents on the regression of left ventricular hypertrophy and myocardial fibrosis, as well as, long-term clinical outcomes in future studies.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Mu Jie Liew
- Phone Number: 67042304 82002052
- Email: liew.mu.jie@nhcs.com.sg
Study Locations
-
-
-
Singapore, Singapore, 169609
- Recruiting
- National Heart Centre Singapore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- 21 years and over
- Physician diagnosed essential hypertension, on at least 1 medication for blood pressure control
- Newly diagnosed hypertension: systolic blood pressure 140mmHg or greater (diastolic blood pressure 90mmHg or greater) on at least 2 office visits (Weber 2013) and not started on any anti hypertensive medications at time of ambulatory blood pressure monitoring
- Resistant hypertension: persistent systolic blood pressure 140mmHg or greater (diastolic blood pressure 90mmHg or greater) despite on at least 3 anti-hypertensive medications (Jennings 2013; Weber 2013)
Exclusion Criteria:
- Known secondary hypertension: renal causes (renal artery stenosis, chronic renal failure); endocrine causes (aldosterone excess, pheochromocytoma, cushing's syndrome, hyperthyroidism); cardiac causes (coarctation of the aorta)
- Contraindications to cardiovascular magnetic resonance: implantable devices, cerebral aneurysm clips, cochlear implants, renal impairment (GRF <30ml/min/1.73m2), claustrophobia and women who are pregnant or breast-feeding
- Limited life expectancy
- On-going unstable medical conditions: hypertensive crisis, acute coronary syndromes or acute heart failure
- History of coronary artery disease, ischemic heart disease
- History of transient ischemic attacks or cerebrovascular events
- History of atrial fibrillation
- History of heart failure
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Newly Diagnosed Hypertension
Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
|
The test studies the structure and function of the eye vessels.
It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
For the evaluation of left ventricular volumes, function and mass.
This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
For the assessment of diastolic and systolic function as well as valvular and cardiac function.
Ventricular-arterial coupling will also be performed.
To examine specific function of the heart.
A 24-hour test.
|
Well-Controlled Hypertension
Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
|
The test studies the structure and function of the eye vessels.
It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
For the evaluation of left ventricular volumes, function and mass.
This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
For the assessment of diastolic and systolic function as well as valvular and cardiac function.
Ventricular-arterial coupling will also be performed.
To examine specific function of the heart.
A 24-hour test.
|
Resistant Essential Hypertension
Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
|
The test studies the structure and function of the eye vessels.
It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
For the evaluation of left ventricular volumes, function and mass.
This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
For the assessment of diastolic and systolic function as well as valvular and cardiac function.
Ventricular-arterial coupling will also be performed.
To examine specific function of the heart.
A 24-hour test.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
First occurrence of cardiovascular event
Time Frame: 10 years
|
Heart failure, Myocardial Infarction, Strokes and Death
|
10 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Calvin WL Chin, MBBS, PhD, National Heart Centre Singapore
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015/2603
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Fibrosis
-
Virginia Commonwealth UniversityWake Forest UniversityRecruitingMyocardial Fibrosis | Myocardial Injury | Chemotherapeutic ToxicityUnited States
-
Johns Hopkins UniversityGuerbetNot yet recruitingMyocardial FibrosisUnited States
-
Medical University of ViennaUnknown
-
Cell Therapy Ltd.Royal Brompton & Harefield NHS Foundation TrustUnknownMyocardial Fibrosis
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Chang Gung Memorial HospitalCompletedFibrosis Myocardial
-
University of EdinburghActive, not recruiting
-
Nanjing First Hospital, Nanjing Medical UniversityRecruiting
-
Shanghai Zhongshan HospitalBeijing Continent Pharmaceutical Co, Ltd.Active, not recruitingMyocardial FibrosisChina
-
University of MessinaNatasha Irrera; Gianluca Di Bella; Antonio Micari; Roberto LicordariRecruitingMyocardial Infarction | Myocardial Fibrosis | Myocardial Remodeling, VentricularItaly
Clinical Trials on Retinal Photography (Optional)
-
IDx LLCThe University of Texas Health Science Center, Houston; University of Pennsylvania and other collaboratorsCompletedDiabetic RetinopathyUnited States
-
Mayo ClinicEyenuk, Inc.; Malavika Bhaskaranand PhD; Kaushal SolankiCompletedAlzheimer Disease | Mild Cognitive Impairment | Vascular DementiaUnited States
-
Centre Hospitalier Universitaire DijonTerminatedEnd-stage Chronic Kidney FailureFrance
-
Emory UniversityCompletedHeadache | Acute, Focal Neurologic Disease | Severely Elevated Blood Pressure | Acute Visual LossUnited States
-
National Heart Centre SingaporeRecruitingMyocardial Ischemia | Cardiovascular Diseases | Coronary Artery Disease | Coronary Heart Disease | Ischemic Heart Disease | Microvascular Coronary Artery DiseaseSingapore
-
Centre Hospitalier Universitaire de NiceTerminatedPremature BirthFrance
-
Yale-NUS CollegeUnknownFood Photography | Non-Food Photography | No Phone UseSingapore
-
Yale-NUS CollegeUnknownFood Photography | Non-Food Photography | No Phone UseSingapore
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Topcon CorporationCompleted